RecruitingEarly Phase 1NCT07275736

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

An Exploratory Clinical Study on the Safety and Efficacy of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases

Sponsor

Juventas Cell Therapy Ltd.

Enrollment

18 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Neurological Autoimmune Diseases

Summary

This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CNCT19 cell injection for people with neurological autoimmune diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.